EXCLUSIVE-Biden to put tariffs on China medical supplies - sources By Jarrett Renshaw and Trevor Hunnicutt May 10 (Reuters) - The Biden administration is expected to issue new tariffs on Chinese-made medical devices like syringes and personal protective equipment when it unveils its new trade strategy next week, according to two sources familiar with the decision.

U.S. RESEARCH ROUNDUP- Paramount Global, Sprout Social, Williams-Sonoma May 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Paramount Global, Sprout Social and Williams-Sonoma ,on Friday. HIGHLIGHTS * Expedia Group Inc EXPE.O : Piper Sandler cuts to neutral from overweight * Paramount Global PARA.O : Seaport Research Partners cuts to neutral from buy * Sprout Social Inc SPT.O : Piper Sandler cuts to neutral from ov

BUZZ-U.S. STOCKS ON THE MOVE-Sarepta, Zoetis, Pioneer Natural Resources Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes advanced on Thursday, a day after the Federal Reserve left interest rates unchanged and signaled a dovish tilt, with focus moving to a crucial job report later in the week.

BUZZ-U.S. STOCKS ON THE MOVE-Becton, Sarepta, Zoetis Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes advanced on Thursday, a day after the Federal Reserve left interest rates unchanged and allayed worries around potential rate hikes, with focus moving to a crucial job report later in the week.

BUZZ-Becton climbs on 2024 profit forecast raise ** Shares of medical device maker Becton Dickinson BDX.N rise ~3.2% to $241.09 ** Co raises its annual profit forecast to $12.95 to $13.15 per share, up from its previous forecast of $12.82 to $13.06 per share ** "Longer term, we remain optimistic on the outlook for BD as the company appears to be well on its way to achieving its BD 2025 commitments" - William Blair analyst Andrew Brackmann ** Co reports Q2 adj.